The Auditory P50 Gating in Mild Cognitive Impairment: A Case-Control Study

Area of Science:

• Neuroscience
• Biomarkers
• Cognitive Impairment

Background:

• Mild Cognitive Impairment (MCI) is a prodromal stage of dementia.
• Neurophysiological changes may serve as early diagnostic biomarkers for MCI.
• Auditory P50 gating is a measure of sensory processing and inhibition.

Purpose of the Study:

• To investigate the impact of MCI on auditory P50 gating.
• To determine if auditory P50 gating can serve as a neurophysiological biomarker for MCI diagnosis.

Main Methods:

• Recruitment of 20 MCI patients and 17 healthy controls.
• Administration of structured questionnaires.
• Performance of auditory P50 gating measurements.

Main Results:

• MCI patients exhibited a significantly higher reduction in P50 gating at the Fz site compared to controls (1.21 ± .68 vs .66 ± .37, P = .00).
• A P50 gating S2/S1 ratio cutoff of 0.5 at the Fz site effectively distinguished MCI patients from controls.
• MCI patients showed a significantly higher P50 average amplitude at the Pz site than controls (2.62 ± 1.20 vs 1.70 ± .74, P = .01).

Conclusions:

• Auditory P50 gating alterations are evident in MCI patients.
• MCI is associated with an impaired ability to inhibit repeated auditory stimuli.
• Auditory P50 gating may function as a neurophysiological biomarker for MCI.